To further characterize this putative EZH2/TCF3/p21 regulatory axis in vivo, we exploited a subcutaneous xenograft tumor model using KLE cells with EZH2 knockdown or TCF3 knockdown individually or simultaneously. The gene discussed is CDKN1A; the disease is neoplasm.